DOCSLIB.ORG

Yale Medicine Magazine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Yale Medicine Magazine yale medicine autumn 2003 ’Round and ’round Local take on For sensory expert, the a global outbreak a taste of success early days of dna 24 30 14 16 autumn 2003 yale medicine CONTENTS 2 Letters 4 Chronicle 8 Rounds 10 Findings 12 Books 13 On Campus 14 Capsule on the cover 16 Building a better drug Academic researchers in pharma- The rational approach to drug discovery is changing cology have long relied on intuition to advance the process of drug pharmacology, but serendipity and imagination still play discovery. Even in today’s more a starring role. technology-driven and “rational” By Marc Wortman environment, there’s nothing like an inspired hunch. 24 Illustration by Gary Clement When a global outbreak becomes local For the shoe-leather work of public health, Connecticut officials seek help from Yale’s disease detectives. By Jennifer Kaylin 30 A matter of taste Debunking myths and shattering stereotypes has long been part of Linda Bartoshuk’s career path. By Peter Farley 34 Faculty 38 Students 46 Alumni 56 Faces 62 In Memoriam 64 Follow-Up 64 Archives On the Web info.med.yale.edu/ymm On our website, readers can submit class notes or a change of address, check the alumni events calendar, arrange for a lifelong Yale e-mail alias through the virtual Yale Station and search our electronic archive. 2 letters from the editor 3 the rest of the profession. The of going to my office and talk- People may think that you are ery. My experience is described The things that matter yale medicine conclusion is obvious: state ing with my patients, then I irrelevant, but as long as you are in a chapter in a book called Alumni Bulletin of the boards should recognize that it will move to another phase of convinced that you are not, you Doctors Afield, published by Yale As one can see from these pages, our mailbag has been Yale University School of Medicine Autumn 2003, Volume 38, No. 1 is their duty to discipline the my life, retirement. have something to say to them. University Press in 1999. bursting lately. Some of the letters affirm an idea expressed Editor-in-Chief repeat offenders and with more Mark W. Lischner, m.d. ’65 Howard M. Spiro, m.d. In my time at the School of in Yale Medicine, while others offer a wholly different per- Michael Kashgarian, m.d. than a tap on the wrist. Roseville, Calif. Professor emeritus of medicine Medicine, there were a number spective. I hope this means we’re covering topics of impor- Professor of Pathology and Biology Frederick W. Goodrich Jr., New Haven of optional courses. Are those tance to readers and presenting a diversity of views on Editor m.d., hs ’49 still offered? If so, I would sug- To my former fellow, Herbert The letter above is excerpted from a Michael Fitzsousa gest an elective on retirement. questions that are too complex to have simple answers. Just Medford, Ore. Kaufmann: I read your recent longer essay by Howard Spiro that Director of Publications Young people entering medicine as the university thrives on the exchange of ideas, so does essay and was delighted at your appears in full on the letters page of Associate Editor often have a narrow view of In reporting on the current medi- eloquence if pained at your our website, info.med.yale.edu/ymm. this magazine. John Curtis the world. Retirement is cer- cal malpractice crisis, author conclusion that doctors should The topics in the Summer issue that drew the greatest Contributing Editors tainly not what they are think- Eli Kintisch characterizes it as a retire. I am grateful as I approach Dear Herbert: I am responding response were physician retirement and the malpractice Sharon McManus ing about. When I retired from battle between doctors and 80 that you left unspecified to your essay and Howard Karen Peart psychiatry and psychoanalysis, insurance debate. Alumnus Herbert Kaufmann’s article on lawyers. The cliché is catchy, but the age for desuetude. You Spiro’s response. You eloquently Cathy Shufro It’s high time to fix I was struck by how many of why he decided to retire while still in his prime (“Know- Jacqueline Weaver it is also misleading. Thousands condoned your own retirement describe how, as we get older, the malpractice mess my colleagues hung on way past Marc Wortman, ph.d. of attorneys in this country, by saying that aging doctors our relationship with our ing When It’s Time to Quit”) was unsolicited but perfect for Your article “Showdown” in the the time when they should have Contributors myself included, devote their pro- grow out of touch with junior medical community changes— the Essay section. For our feature on the malpractice debate Summer issue of Yale Medicine quit. They had nothing else to Peter Farley fessional careers to defending colleagues who prefer their a discomfort and reality all (“Showdown”), we did ask readers for their opinions and brings out the sorry state of do. Some planning earlier in life Jennifer Kaylin health care providers and hospi- own peer group anyway, that physicians must experience. At Nancy Ross-Flanigan affairs in the medicolegal cli- would have served them well. received a great number in reply. The letters are still coming. tals in medical malpractice cases older practitioners no longer some point in time, I agree, it Karen Schmidt mate. When I began the practice Next we’re turning our focus to bioethics, a growth and advocating for tort reform understand the science in medi- would be wise to retire. At what George W. Naumburg Jr., m.d. ’45 Colleen Shaddox of ob/gyn after World War II, measures that limit physician lia- cal journals and that—in your point in time this happens will North Salem, N.Y. area in science and medicine if ever there was one—and an Copy Editing my malpractice insurance was bility. This is not a case of doctor words—they grow irrelevant depend on the individual. area of increasing strength at Yale. For our Spring issue, Anne Sommer $25 a year. versus lawyer; it is both broader as far as their colleagues are Change in life is inevitable Thanks for the news we’d like to hear from you about the ethical dilemmas you Office Manager / Editorial Assistant m.d. Albert W. Diddle, ’36 and more refined than that. At concerned. and we all respond differently. from Cedar Street have faced in your professional life. We will then pose the Claire M. Bessinger Knoxville, Tenn. Your response, seemingly, was to best, the generalization oversim- I failed you as a teacher if Again I am awed by this spec- thorniest of these problems to a panel of bioethics experts Senior Administrative Assistant / retire; Howard’s was to adapt to Website Coordinator plifies the nuances of the debate. you imagine that most of the tacular publication you have The lucid comments about the it by accepting a “changed role”; from the Yale faculty. Please send your story to: Ethics, Cheryl R. Violante At worst, it serves to perpetu- people who come to see me crafted with its singular breadth malpractice situation and its and mine was to create a new Yale Medicine, P.O. Box 7612, New Haven, CT 06519-0612 Design ate the misguided animosity that, require that I trace the twists and depth, sensitivity and his- aggravations were apt and career. I also retired three years or by e-mail to [email protected]. We’ll publish a selection of Daphne Geismar sadly, polarizes the professions and turns of amino acids. It may torical continuity. Yale Medicine helpful in understanding the ago, and although I loved the Printing and leaves patients stranded be fun to read the latest science, is one of many publications dilemmas, along with responses from our resident experts, dilemma. However they failed medical community that I left Moore Wallace Andrews somewhere in the middle. but little of that is required to I receive but the only one in Yale Medicine and on our website, info.med.yale.edu/ymm. to mention one of the major behind, I decided to enter a Yale Medicine is distributed to alumni, Ken Baum, m.d. ’01, j.d. ’01 care for patients in the office or I devour from cover to cover. And since it is next to impossible to find universal agree- faculty, students and friends of the causes of premium increases, New Haven clinic. There are nowhere near new field and way of life. I have Congratulations and thanks for ment on the things that really matter, expect to see more School of Medicine, as well as leaders which is the failure of state enough physicians, and we who been auditing courses at the More letters on this topic appear on an outstanding contribution to in Yale University alumni activities. medical examiners boards to take are spared can make a contribu- Yale School of Forestry and Envi- letters to the editor. our website, info.med.yale.edu/ymm. generations of Yale physicians. Abbreviations commonly used steps to reduce the number of tion by working part time in ronmental Studies and am Glenn L. Kelly, m.d. ’62, hs ’66 Michael Fitzsousa in Yale Medicine include hs to denote compensable medical errors. an office or clinic to let someone volunteering as a stewardship Knowing when not Englewood, Colo. michael.fi[email protected] the final year of residency for house For some years the Public else bear the heavier burdens coordinator for a land trust. staff, fw for the final year of a fellow- Citizen Health Research Group to retire of the hospital.
Load more

Recommended publications
  • Background to the Celebration of Herbert D. Kleber (1904 -2018) by Thomas A
    1 Background to the Celebration of Herbert D. Kleber (1904 -2018) by Thomas A. Ban By the mid-1990s the pioneering generation in neuropsychopharmacology was fading away. To preserve their legacy the late Oakley Ray (1931-2007), at the time Secretary of the American College of Neuropsychopharmacology (ACNP), generated funds from Solway Pharmaceuticals for the founding of the ACNP-Solway Archives in Neuropsychopharmacology. Ray also arranged for the videotaping of interviews (mainly by their peers) with the pioneers, mostly at annual meetings, to be stored in the archives. Herbert Kleber was interviewed by Andrea Tone, a medical historian at the Annual Meeting of the College held in San Juan, Puerto Rico, on December 7, 2003 (Ban 2011a; Kleber 2011a). The endeavor that was to become known as the “oral history project” is based on 235 videotaped interviews conducted by 66 interviewers with 213 interviewees which, on the basis of their content, were divided and edited into a 10-volume series produced by Thomas A. Ban, in collaboration with nine colleagues who were to become volume editors. One of them, Herbert Kleber, was responsible for the editing of Volume Six, dedicated to Addiction (Kleber 2011b). The series was published by the ACNP with the title “An Oral History of Neuropsychopharmacology Peer Interviews The First Fifty Years” and released at the 50th Anniversary Meeting of the College in 2011 (Ban 2011b). Herbert Daniel Kleber was born January 19, 1934, in Pittsburgh, Pennsylvania. His family’s father’s side was from Vilnius, Lithuania, and the Mother’s side was from Germany. Both families came to the United State during the first decade of the 20th century.
    [Show full text]
  • July 2020 Strategies for Emerging Infectious Diseases
    THE AMERICAN WWW.CAYMANCHEM.COM ASSOCIATION OF IMMUNOLOGISTS AT ISSUE NEW THE DOWNLOAD Virus Life Cycle Infographic Infographic Cycle Life Virus JULY 2020 Resources for Your Research Your for Resources Informative Articles Informative CAYMAN CURRENTS: CAYMAN IN THIS ISSUE OF THE THE OF ISSUE THIS IN DISEASES INFECTIOUS EMERGING AAI Looks Back: How Honolulu’s Chinatown FOR STRATEGIES "Went Up in Smoke" A history of the first plague outbreak in Hawai’i, page 30 ANTIVIRAL 28 No. Permit CAYMAN CURRENTS PA Gettysburg, PAID 20852 20852 20852 20852 MD MD MD MD Rockville, Rockville, Rockville, Rockville, 650, 650, 650, 650, Suite Suite Suite Suite Pike, Pike, Pike, Pike, Rockville Rockville Rockville Rockville 1451 1451 1451 1451 Postage U.S. Non-Proft Org. Non-Proft IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS OF OF OF OF ASSOCIATION ASSOCIATION ASSOCIATION ASSOCIATION AMERICAN AMERICAN AMERICAN AMERICAN THE THE THE THE 2020 advanced Course in Immunology Now Virtual! I July 26–31, 2020 IN THIS ISSUE Director: Wayne M. Yokoyama, M.D. Washington University School of Medicine in St. Louis x4 Executive Offce The American Association Don’t miss the premier course in immunology for research scientists! of Immunologists x8 Public Affairs This intensive course is directed toward advanced trainees and scientists who wish to expand or update 1451 Rockville Pike, Suite 650 their understanding of the feld. Leading experts will present recent advances in the biology of the Rockville, MD 20852 20 Members in the News immune system and address its role in health and disease. This is not an introductory course; Tel: 301-634-7178 attendees will need to have a frm understanding of the principles of immunology.
    [Show full text]
  • Coalition Communication: Healthcare
    Updated 1/15/2021 Coalition Communication: Healthcare COVID-19 UPDATES We need your help in sharing information about the COVID-19 vaccine. KEY STATS Vaccine.coronavirus.ohio.gov is an online resource for Ohioans to learn which providers received a COVID-19 vaccine allotment and how to contact them. Data as of 1/14/2021 Tentative dates to start vaccinating these Phase 1B populations are: • Jan. 19, 2021—Ohioans 80 years of age and older. PUBLIC HEALTH • Jan. 25, 2021—Ohioans 75 years of age and older; those with severe ADVISORY SYSTEM congenital or developmental disorders. • Feb. 1, 2021—Ohioans 70 years of age and older; employees of K-12 schools that wish to remain or return to in-person or hybrid learning. • Feb. 8, 2021—Ohioans 65 years of age and older. When a new age group begins, vaccinations may not be complete for the previous age group. It will take a number of weeks to distribute all of the vaccines given the limited doses available. If you are older than 65, please connect with an Area Agencies on Aging about questions or if you need transportation assistance. For more information, visit aginig.ohio.gov or call 1-866-243-5678. More information can be found at coronavirus.ohio.gov. 21-DAY TRENDS INDUSTRY INFORMATION Case Average 7,316 ■ The Ad Council and the COVID Collaborative have released a series of Death Average 73 videos, available in a YouTube playlist, feature an introduction from Dr. Anthony Fauci and include experts leading healthcare organizations. Hospitalization 293 Average ■ BlackDoctor.org’s Making It Plain: What Black America Needs to Know ICU Admission 29 About COVID-19 and Vaccines aired on January 7 and is now available on- Average demand on YouTube.
    [Show full text]
  • Do Vaccines Reduce Long-COVID Symptoms?
    Do Vaccines Reduce Long-COVID Symptoms? One of the many important questions about long-COVID is whether COVID-19 vaccination can reduce symptoms in those experiencing long-COVID. While some patients report a lessening of symptoms, it is unknown whether this is causally related to the vaccine, or merely reflective of the fact that most patients’ symptoms improve over time. In addition, some patients also report a worsening of symptoms. But since there is currently a poor understanding of the causes and risk factors for long-COVID, all patient experiences following vaccination need to be carefully assessed. For example, one observational and uncontrolled study (not yet peer-reviewed) released in March 2021 compared 44 vaccinated long-COVID patients with 22 “I’ve heard from people who say they no longer matched unvaccinated participants. Those who received the vaccine showed a have ‘brain fog,’ their gastrointestinal problems small overall improvement in long-COVID symptoms, with a decrease in have gone away, or they stopped suffering from worsening symptoms (5.6% vaccinated vs. 14.2% unvaccinated) and increase in the shortness of breath they’ve been living with symptom resolution (23.2% vaccinated vs. 15.4% unvaccinated).1 Additionally, since being diagnosed with COVID-19.” an informal survey of more than 900 patients with long-COVID by Survivor - Akiko Iwasaki, PhD Corps, a patient advocacy group for those with long-COVID, found that only Professor of immunobiology at Yale School of 39% of patients reported improvements following vaccination.
    [Show full text]
  • Overview of Antiviral Medications Used in Ophthalmology
    ANTIVIRALS Overview of antiviral medications Jeremy Hoffman Clinical Research used in ophthalmology Fellow: International Centre for Eye Health, As eye health professionals, London School of Hygiene & Tropical we are fortunate to have Medicine, UK. a number of antiviral medications available in our armoury to treat a range of ophthalmic viral infections. This article provides an overview of what antiviral agents are available for these conditions, detailing their regimen SANDIP DAS SANYAM (SAGARMATHA CHOUDHARY EYE HOSPITAL, NEPAL) SANDIP DAS SANYAM(SAGARMATHA and evidence that Aciclovir – either as topical eye ointment or systemic tablets – is still the first-line antiviral in the treatment of many viral eye diseases around the supports their use. world, including here in Nepal. phthalmic viral infections, particularly herpes associated with toxicity, including superficial punctate simplex keratitis, have been at the forefront of keratopathy, chemical conjunctivitis, punctal occlusion Othe development of antiviral medications. and occasional serious hypersensitivity reactions. Idoxuridine was also unable to penetrate the corneal The discovery of the first targeted antiviral agent, epithelium to treat stromal or endothelial keratitis. in common with penicillin (the first antibiotic), owes much to serendipity. In 1959, William Prusoff With the advent of aciclovir in 1982, most herpetic developed idoxuridine (IDU) as a potential systemic ophthalmic infections became treatable, including anti-cancer agent. Idoxuridine those caused by herpes
    [Show full text]
  • Enhancing the Lives of Those We Serve TABLE of CONTENTS
    2014 ANNUAL REPORT ENHANCING THE LIVES OF THOSE WE SERVE TABLE OF CONTENTS page SANDRA PEARSON 03 Life after Cancer? Bring It on… page RICHARD KENNEY Cutting-edge heart procedures 05 keep him on the move page ZAILYN BYRD A rough start leads to a smoother 07 road ahead… page FATHER JOHN GEORGIA 09 Grateful for the gift of life Enhancing the Lives of Those We Serve 2 Life after cancer? Bring it on… It was February 2013, and Sandra Pearson will never forget the words she heard on the other end of the telephone. “We are sorry to inform you that the test results are positive.” She had breast cancer. A couple of weeks earlier, her doctor had discovered a lump in Sandra’s breast. At the suggestion of her good friend, Sandra went to Smilow Cancer Hospital at Yale-New Haven where she met with Anees Chagpar, MD, director of the Breast Center at Smilow for an exam and more testing. Sandra recalls her first thoughts. This can’t be... I have two children… I run a daycare center… I have lots of people depending on me… I can’t have Sandra works with a personal trainer, Derek. cancer. The morning after that life-changing phone call, Sandra, along with six supportive family members, headed into Smilow to talk about next steps. “First, Dr. Chagpar hugged me. She comforted me. Then, she explained what my test results revealed. She took her time, drew pictures and diagrams, answered questions and explained possible scenarios. Dr. Chagpar was so patient and attentive that she made me feel as if I was her one and only patient.” Next steps would include four months of chemotherapy, then surgery to remove the tumor followed by radiation treatments.
    [Show full text]
  • Meeting Report: 26Th International Conference on Antiviral Research Q
    Antiviral Research 100 (2013) 276–285 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Meeting report: 26th International Conference on Antiviral Research q R. Anthony Vere Hodge Vere Hodge Antivirals Ltd, Old Denshott, Leigh, Reigate, Surrey, UK article info abstract Article history: The 26th International Conference on Antiviral Research (ICAR) was held in San Francisco, California from Received 2 August 2013 May 11 to 15, 2013. This article summarizes the principal invited lectures at the meeting. The opening Accepted 8 August 2013 symposium on the legacy of the late Antonín Holy´ included presentations on his pioneering work with Available online 21 August 2013 nucleotide analogs, which led to the development of several antiviral drugs including tenofovir. This drug has transformed the treatment of HIV infection and has recently become the first-line therapy for chronic Keywords: hepatitis B. The Gertrude Elion Award lecturer described the anti-HIV activities of the CCR5 inhibitor Human immunodeficiency virus cenicriviroc and the reverse transcriptase inhibitor festinavirÒ, and also reviewed the evaluation of bio- Hepatitis B degradable nanoparticles with adjuvant activity. The William Prusoff Award winner reported on the cre- Hepatitis C Herpesviruses ation of NAOMI, a computer model with 21 enzymes to predict the activity of nucleoside analogs against Antiviral therapy hepatitis C virus (HCV). Other invited lecturers discussed the development of countermeasures against severe dengue and the potential of RNA virus capping and repair enzymes as drug targets. Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; the evaluation of single-tablet regimens for HIV infection; and the investiga- tion of cytomegalovirus resistance to CMX001.
    [Show full text]
  • Inland Communities of Color Receiving Vaccinations at Slower Rate, Data Shows – Press Enterprise ___
    2/4/2021 Inland communities of color receiving vaccinations at slower rate, data shows – Press Enterprise ___ NEWS •• News Inland communities of color receiving vaccinations at slower rate, data shows Victorville resident Marvin Abella, 32, receives his second vaccination shot of the Pfizer-BioNTech COVID-19 Vaccine by licensed vocational nurse Mayra Aceves at Arroyo Valley High School in San Bernardino on Thursday, Jan. 28, 2021. 500 second doses were scheduled to be given out Thursday with another 500 scheduled for Friday. (Photo by Will Lester, Inland Valley Daily Bulletin/SCNG) By DEEPA BHARATH || [email protected] || OrangeOrange CountyCounty Register PUBLISHED: February 3, 2021 at 6:42 p.m. || UPDATED:UPDATED: February 3, 2021 at 6:42 p.m. https://www.pe.com/2021/02/03/inland-communities-of-color-receiving-vaccinations-at-slower-rate-data-shows/?utm_medium=social&utm_c… 1/8 2/4/2021 Inland communities of color receiving vaccinations at slower rate, data shows – Press Enterprise Communities of color are behind when it comes to being vaccinated for the coronavirus, a disparity Inland Empire officials say they are working to address. In Riverside County, where 50% of the population is Latino, for example, only 17.9% of those who have been vaccinated are Latino while 44.9% are White, county officials said Wednesday, Feb. 3. Meanwhile, 4.1% of the total number of vaccinations administered have been given to African Americans and 10.7% toto AsianAsian Americans,Americans, whichwhich eacheach representrepresent aboutabout 6.5%6.5% ofof thethe countyʼscountyʼs population. Native American and Pacific Islander residents, who represent 0.8% and 0.3% of the population, respectively, account for 0.6% and 0.7% of thosethose vaccinated.vaccinated.
    [Show full text]
  • Applications of Traditional Chinese Medicine in Antiviral and Anticancer Drug Development
    YALE JOURNAL OF BIOLOGY AND MEDICINE 93 (2020), pp.381-384. Interview Applications of Traditional Chinese Medicine in Antiviral and Anticancer Drug Development An Interview with Dr. Yung-Chi (Tommy) Cheng, PhD Huaqi Li* MPH Candidate, Yale School of Public Health, Yale University, New Haven, CT You studied chemistry in Taiwan and then went During that period, there was a course offered at into a PhD in biochemical pharmacology at Brown University that invited several pharmacology Brown University. Can you tell us about how professors from other campuses to teach. Among those you first became interested in these fields? was Professor Prusoff who was an expert in antiviral and I was always interested in chemistry and the biologi- cancer research. He synthesized the first antiviral drug cal aspects of chemistry, so my undergraduate major was for the herpes simplex virus (HSV) and I was interested actually a double major in chemistry and biology. So, in that subject, so I decided to do my postdoc with him when I was deciding what to do after my undergraduate at Yale. I came over after receiving my PhD degree and training, I decided to go abroad and applied to universities that was the first time I was exposed to virology. Through in Canada. I was at the University of Guelph for one year. bioassays, we identified a nucleoside analog that was My wife was studying at Brown University, so I reapplied highly selective against HSV-1 and then the question was to Brown, but they didn’t really have a biochemistry de- how could this compound have such selectivity? Because partment, so I needed to decide what specific specialty of before that time, nobody believed that you could come biochemistry I was interested in.
    [Show full text]
  • Newsletter Spring 2021
    A Year Like No Other - the 2020 UGSP Newsletter Written and Assembled by UGSP Newsletter Committee Charlesice Grable-Hawkins (Chair), Nyree Riley, Makheni Jean-Pierre “Each time new experiments are observed to agree with the predictions the theory survives, and our confidence in it is increased; but if ever a new observation is found to disagree, we have to abandon or modify the theory.” - Dr. Stephen Hawking From the global push to develop a vaccine, institutional restructuring, and changing schedules to the massive transition into a virtual environment, the year of 2020 was nothing like anyone could have planned for. This near universal experience has led many to reassess the working model of their everyday lives, to reflect and experiment with how they approach their wellness and their connections with others, and to think critically about moving forward. The Undergraduate Scholarship Program, under the direction of Dr. Darryl Murray, continues to support students who are from disadvantaged backgrounds and who are passionate about advancing biomedical, behavioral, and social science fields for the improvement of human health. This newsletter will highlight some of the ways in which current UGSP scholars have adapted to the challenges of 2020, provide insight into the perspective of both a mentee and mentor, as well as how UGSP alumni Dr. Kizzmekia Corbett has contributed to the development of the Moderna SARS-CoV-2 vaccine. Table of Contents Dr. Kizzmekia Corbett – a Powerful Voice in Science During COVID-19 ....................................................... 2 Current Scholars ............................................................................................................................................ 3 UGSP Alum and Mentor Reflections ............................................................................................................. 4 Dr. Darryl Murray’s go-to wellness activity over this past year has been walking his family’s new rescue dog Pepper! Dr.
    [Show full text]
  • Remarks by Jon Soderstrom*
    REMARKS BY JON SODERSTROM* Senator Birch Bayh has made the most significant impact on the U.S. and global economy of any individual who has ever come before and who lives today, full stop. That’s an amazing accomplishment. We have heard about all the legislative feats that he accomplished. We’ve heard about what an amazing legislator, attorney, and public servant he was. But, there are very few human beings who have had the impact on our economy that Senator Bayh had. It’s an amazing accomplishment and something that we should be in awe of. I’m going to give you a few statistics. I’m not going to overwhelm you; I’m going to bring it down to a personal level. I promised Kitty that I wouldn’t cry. Because when I was thinking about this the other day, it’s hard. If you knew Senator Bayh, he wore his emotions on his sleeve, and we have cried together. Here are just a couple statistics that should blow you away. The Bayh- Dole Act1 unleashed the technologies that were being developed in universities in a way that no one probably could have imagined. It was immediate and it was dramatic. The year was 1980. Prior to 1980—and I know because my entire career arc has followed the senator’s accomplishments—I was at graduate school studying the economy and what patents were doing, et cetera. At that time, the federal government, by law, was the owner of all intellectual property created with federal dollars and, as a result, it had created 28,000 patents.2 Less than 5 percent of those patents had ever been licensed or commercialized, compared with 25 percent to 30 percent of the small number of federal patents for which the government had allowed companies to retain title to the invention.3 That is “because the government would only grant nonexclusive licenses to patents it owned,” so * Managing Director, Office of Cooperative Research at Yale University.
    [Show full text]
  • ISAR News Vol
    August 2013 ISAR News Vol. 23 No. 1 Report on the 26th ICAR 11–15 May 2013, San Francisco, CA, USA President’s message (Phillip Furman) and Scientific Meeting Report. They have been inte- gral in maintaining a productive working relationship The 26th ICAR is now behind us and I am pleased to with Elsevier, publisher of Antiviral Research and report that the conference was a great success. The So- International Medical Press, publisher of Antiviral ciety has invested a significant amount of work over Therapy. The Society wishes to thank International the past years in revitalizing the annual meeting. Medical Press for publishing ISAR News for several These efforts have been recognized and affirmed by years and for publishing issue 22.2 in the last issue the results of our post-conference surveys, which pro- of AVCC (February 2013) which has now ceased pub- vided considerable positive feedback along with con- lication. Because of this, the Society had no publisher structive suggestions and comments. Thanks to all of for ISAR News. Thanks to the efforts of Mike Bray, you who have responded to these important surveys. Hugh Field, and Anthony Vere Hodge, Elsevier will The success of this year’s ICAR is due to a talented now publish ISAR News and the Scientific Meeting team of dedicated individuals with whom I had the Report in Antiviral Research. The smooth transition privilege of working to plan the conference. First, was greatly assisted by Alina Helsloot (Elsevier) who thanks go to the ISAR officers Joe Colacino, Past Pre- came to ICAR.
    [Show full text]